Cann Group Ltd
ASX:CAN
Cann Group Ltd
ASX:CAN
Price:
0.006
AUD
Market Closed
Market Cap:
AU$9.5m
Relative Value
The Relative Value of one
CAN
stock under the Base Case scenario is
0.055
AUD.
Compared to the current market price of 0.006 AUD,
Cann Group Ltd
is
Undervalued by 89%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CAN
Relative Value
Base Case
0.055
AUD
Undervaluation 89%
Multiples Across Competitors
CAN Competitors Multiples
Cann Group Ltd Competitors
Cann Group Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Cann Group Ltd
ASX:CAN
|
9.4m AUD | 0.8 | 0.6 | -2.2 | -2.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
866.9B USD | 13.3 | 42 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.1B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 4 | 18.9 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218B GBP | 5 | 28.6 | 15.9 | 22.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF | 5.2 | 20.8 | 12.9 | 16.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.9B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117B USD | 2.4 | 16.6 | 7 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
